Sacubitril/valsartan vs angiotensin receptor inhibition in heart failure: A real‐world study in Taiwan
ESC Heart Failure Jul 31, 2020
Chang PC, Wang CL, Hsiao FC, et al. - Using data from the Chang Gung Research Database, researchers compared angiotensin receptor–neprilysin inhibitor therapy vs angiotensin receptor blocker (ARB) therapy in terms of efficacy for cardiovascular outcomes in patients experiencing heart failure (HF) with reduced ejection fraction. They performed 1:1 propensity score matching based on age, gender, and baseline left ventricular ejection fraction. Findings demonstrated the superiority of sacubitril/valsartan over ARB therapy in decreasing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular mortality in patients suffering from HF with reduced ejection fraction.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries